Abstract
Fibric acid derivatives are used to treat hyperlipidemia and have wide ranging effects on lipid metabolism. The action of these compounds on cholesterol esterification, catalyzed by acyl-coenzyme A:cholesterol acyltransferase (ACAT), has been quite widely studied, but their effect on cholesteryl ester hydrolysis and the enzyme neutral cholesteryl ester hydrolase (nCEH) has been largely ignored. Male rats were therefore fed for 10 d on a standard chow diet supplemented with either clofibrate or bezafibrate, to study their effects on plasma lipid levels and hepatic cholesterol metabolism. Plasma triacyglycerols were not significantly altered by these diets, but bezafibrate significantly lowered plasma cholesterol levels (29.7%,P<0.01). When expressed per unit weight of DNA, both fibrates reduced the hepatic content of triacylglycerol, cholesterol and cholesteryl esters (40, 18.7, 16.5 and 66.7, 28.6, 34.2% for clofibrate and bezafibrate, respectively). ACAT activity was significantly reduced by both drugs, but clofibrate (65% inhibition) was more effective than bezafibrate (35% inhibition). The most dramatic effect of the diets was a marked increase in the activity of both the microsomal and the cytosolic nCEH. When expressed on a whole liver basis, the effect of bezafibrate on the cytosolic enzyme (13.6-fold increase in activity) was much greater than that of clofibrate (4.8-fold increase). Increases in the activity of a cytosolic protein that inhibits the activity of nCEH were also noted, but these changes were relatively small. The results suggest that the activation of nCEH, in combination with the inhibition in ACAT activity, contributes to a decrease in the cholesteryl ester content of the liver which may influence the secretion of very low density lipoprotein.
Similar content being viewed by others
Abbreviations
- ACAT:
-
acyl-coenzyme A:cholesterol acyltransferase
- C:
-
cholesterol
- CE:
-
cholesteryl ester
- nCEH:
-
neutral cholesteryl ester hydrolase
- HMG-CoA:
-
3-hydroxy-3-methylglytaryl coenzyme A
- SEM:
-
standard error of the mean
- TRIS:
-
tris(hydroxymethyl)-aminomethane
- VLDL:
-
very low density lipoprotein.
References
Vessy, B., Lithell, H., and Ledermann, H. (1982)Atherosclerosis 44, 113–118.
Shepherd, J., Packard, C.J., Stewart, J.M., Atmeh, R.F., Clark, R.S., Boag, D.E., Carr, K., Lorimer, A.R., Ballantyne, D., Morgan, H.G., and Lawrie, T.D.V. (1984)J. Clin. Invest. 74, 2164–2177.
Packard, C.J., Clegg, R.J., Dominiczak, M., Lorimer, A.R., and Shepherd, J. (1986).J. Lipid Res. 27, 930–938.
Stahlberg, D., Angelin, B., and Einarsson, K. (1989)J. Lipid Res. 30, 953–958.
Stahlberg, D., Reihner, E., Ewerth, S., Einarsson, K., and Angelin, B. (1991)Eur. J. Clin. Pharmacol. 40, S33-S36.
Kazumi, T., Maeda, T., Masuda, T., Ishida, Y., Yoshino, G., and Yoshida, M. (1991)Current Therapeutic Res. 50, 50–55.
Brown, M.S., Ho, Y.K., and Goldstein, J.L. (1980)J. Biol. Chem. 255, 9344–9352.
Tabas, I., Roscoff, W.J., and Boykow, G.C. (1988)J. Biol. Chem. 263, 1266–1272.
Hudson, K., and Day, A.J. (1982)Atherosclerosis 45, 109–113.
Castillo, M., Burgos, C., Rodriguez-Vico, F., Zafra, M.F., and Garcia-Peregrin, E. (1990)Life Sci. 46, 397–403.
Turley, S.D., and Dietschy, J.M. (1980)J. Cardiovascular Pharmacol. 2, 281–297.
Einarsson, K., and Angelin, B. (1987)Eur. J. Clin. Invest. 17, 396–407.
Hudson, K., and Day, A.J. (1981)Atherosclerosis 40, 53–63.
Hudson, K., Mojumder, S., and Day, A.J. (1983)Exp. Molec. Pathol. 38, 77–81.
Shand, J.H., and West, D.W. (1992)Lipids 27, 406–412.
Shand, J.H., and West, D.W. (1992),Lipids 27, 413–417.
Shand, J.H., and West, D.W. (1991)Lipids 26, 150–154.
Shand, J.H., West, D.W., McCartney, R.J., Noble, R.C., and Speake, B.K. (1993)Lipids 28, 621–625.
Batzri, S., and Korn, E.D. (1973)Biochim. Biophys. Acta 298, 1015–1019.
Folch, J., Lees, M., and Sloane-Stanley, G.N. (1957)J. Biol. Chem. 226, 497–509.
Gamble, W., Vaughan, M., Kruth, H.S., and Avigan, J. (1978)J. Lipid Res. 19, 1068–1070.
McGowan, M.W., Artiss, J.D., Strandbergh, D.R., and Zak, B. (1983)Clin. Chem. 29, 538–542.
Bradford, M.M. (1976)Anal. Biochem. 72, 248–254.
Labarca, C., and Paigen, K. (1980)Anal. Biochem. 102, 344–352.
Ghosh, S., Kounas, M.Z., and Grogan, W.M. (1990)Lipids 25, 221–225.
Hartig, F., Stegmeier, K., and Hebold, G. (1982)Ann. N.Y. Acad. Sci. 386, 464–467.
Gerondaes, P., Alberti, K.G.M.M., and Agius, L. (1988)Biochem. J. 253, 161–167.
Fleishner, G., Meijer, D.K.F., Levine, W.G., Gatmaitan, Z., Gluck, R., and Arias, I.M. (1975)Biochem. Biophys. Res. Commun. 67, 1401–1407.
Veerkamp, J.H., Peeters, R.A., and Maatman, R.G.H.J. (1991)Biochim. Biophys. Acta 1081, 1–24.
Lazarow, P.B., Shio, H., and Leroy-Houyet, M.A. (1982)J. Lipid Res. 23, 317–326.
Green, S. (1992)Biochem. Pharmacol. 43, 393–401.
Schoonjans, K., Staels, B., Grimaldi, P., and Auwerx, J. (1993)Eur. J. Biochem. 216, 615–622.
Catapano, A.L. (1992)Pharmacol. Res. 26, 331–340.
Hahn, S.E., and Goldberg, D.M. (1992)Biochem. Pharmacol. 43, 625–633.
Villanueva, C., Fabregat, I., and Machado, A. (1989)Biochem. Pharmacol. 38, 2505–2510.
Khan, B.V., Fungwe, T.V., Wilcox, H.G., and Heimberg, M. (1990)Biochim. Biophys. Acta 1044, 297–304.
Kam, N.T.P., Albright, E., Mathur, S.N., and Field, F.J. (1989)J. Lipid Res. 30, 371–377.
Walli, A.K., and Seidel, D. (1981)Res. Exp. Med. 179, 153–161.
Stegmeier, K., Stork, H., Lenz, H., Leuschner, F., and Liede, V. (1980) inLipoproteins and Coronary Heart Disease (Greten, H., Lang, P.D., and Schettler, G., eds.) pp. 76–82, Gerhard Witzstrock, New York.
Strange, E.F., Fruhholz, M., Osenbrugge, M., Reimann, F., and Ditschuneit, H. (1991)Eur. J. Clin. Pharmacol. 40 [Suppl. 1], S37-S40.
Einarsson, K., and Angelin, B. (1986)Atheroscler. Rev. 15, 67–97.
Dietschy, J.M., Turley, S.D., and Spady, D.K. (1993)J. Lipid Res. 34, 1637–1659.
Bilhartz, L.E., Spady, D.K., and Dietschy, J.M. (1989)J. Clin. Invest. 84, 1181–1187.
Nervi, F., Bronfman, M., Allalon, W., Depiereux, E., and Del Pozo, R. (1984)J. Clin. Invest. 74, 2226–2237.
Stone, B.G., Erickson, S.K., Craig, W.Y., and Cooper, A.D. (1985)J. Clin. Invest. 76, 1773–1781.
Author information
Authors and Affiliations
About this article
Cite this article
Shand, J.H., West, D.W. The effects of clofibrate and bezafibrate on cholesterol metabolism in the liver of the male rat. Lipids 29, 747–752 (1994). https://doi.org/10.1007/BF02536695
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02536695